Novo Nordisk A/S is headed for its biggest drop in 3 1/2 years after the world’s biggest maker of insulin trimmed its sales and profit forecasts for the year, signaling intensifying pricing pressure from customers in its largest market.
Profit this year is likely to climb as much as 8 percent, down from an earlier projection of as much as 9 percent, the Bagsvaerd, Denmark-based company said in a statement on Friday.
Profit this year is likely to climb as much as 8 percent, down from an earlier projection of as much as 9 percent, the Bagsvaerd, Denmark-based company said in a statement on Friday.
